Advertisement
U.S. markets close in 6 hours 7 minutes
Advertisement

Daxor Corporation (DXR)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
7.750.00 (0.00%)
As of 03:18PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close7.75
Open7.11
Bid7.75 x 1000
Ask7.84 x 1000
Day's Range7.75 - 7.75
52 Week Range7.11 - 13.13
Volume6,289
Avg. Volume1,944
Market Cap37.14M
Beta (5Y Monthly)-0.30
PE Ratio (TTM)N/A
EPS (TTM)-0.08
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJan 05, 2018
1y Target Est23.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
-6% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for DXR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Daxor Corporation
    Analyst Report: Edwards Lifesciences CorporationSpun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. Its key products include surgical tissue heart valves, transcatheter valve technologies, surgical clips, catheters, and monitoring systems used to measure a patient's heart function during surgery. The firm derives about 55% of its total sales from outside the U.S.
    Rating
    Fair Value
    Economic Moat
    3 years agoMorningstar
View more
  • GlobeNewswire

    New Randomized Controlled Trial Demonstrates the Efficacy of Daxor’s BVA Guided-Care in Heart Failure Patients

    Data From Study Funded by NIH Presented at the American Heart Association Annual Meeting Oak Ridge, TN, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces the presentation of data from a Phase I National Institute of Health (NIH) sponsored randomized control trial (RCT) from two Veterans Affairs Medical Centers (Boston , Minneapolis), validating treatment decisions guided by the Company’s BVA-100® diagnosti

  • GlobeNewswire

    Daxor Corporation Awarded New Patent for Remote Monitoring of Blood Volume

    Patent Covers Novel Optimization of Care by Remote Monitoring Devices Including Smartwatches Oak Ridge, TN, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces that Daxor was recently granted a patent for a system to provide remote blood volume monitoring after initial testing with Daxor BVA-100® (Blood Volume Analyzer) diagnostic. This U.S. patent number (US 11,801,002 B2) adds to our existing portfolio tha

  • GlobeNewswire

    Expert Panelists Advocate Use of Daxor’s Technology to Optimize Treatment at Heart Failure Society of America Annual Scientific Meeting

    Leading Clinicians Highlight Significant Outcome Improvements with Daxor’s Blood Volume Analysis Innovative Technology Oak Ridge, TN, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces that experts recommend the use of blood volume analysis (BVA) to guide optimal treatment in heart failure patient at two Scientific Sessions held during the Heart Failure Society of America Annual Scientific Meeting on Octobe